MediciNova (MNOV) Insider Nicole Lemerond Buys 44,500 Shares

Nicole Lemerond, an insider, bought 44,500 shares of MediciNova, Inc. (NasdaqGM: MNOV) on June 23, 2026. This transaction was not part of a planned purchase, and the shares were acquired without a specified price.

Insider Buying and Selling at MediciNova, Inc.

On June 23, 2026, several insiders, including Nicole Lemerond, Carolyn Beaver, and Hideki Nagao, each acquired 44,500 shares of MediciNova. Earlier in the year, on January 16, 2026, Kazuko Matsuda, the Chief Medical Officer, and Yuichi Iwaki, the President and CEO, also bought 350,000 and 450,000 shares, respectively.

Other Institutional Activity in MediciNova

Vanguard Capital Management LLC opened a new position in MediciNova, ending with 611,039 shares valued at about $837,123. Geode Capital Management, LLC increased its holdings by 14,260 shares, bringing its total to 543,843 shares worth approximately $745,254, a 2.7% increase. BlackRock, Inc. added 984 shares, holding a total of 705,954 shares valued at roughly $967,157. Essex Woodlands Management, Inc. and Citigroup Inc maintained their positions without any changes.

MediciNova, Inc. Stock Down 60.5%

Shares of MediciNova, Inc. traded near $1.31 on Friday. The company, with a market cap of about $64.5 million, operates in the biotechnology sector. It has a forward P/E ratio of -3.05, indicating it is not profitable. The stock has ranged from $1.17 to $1.96 over the past 52 weeks, with a 50-day moving average of $1.36 and a 200-day moving average of $1.41. MediciNova has a current ratio of 9.09 and a quick ratio of 8.91, with a debt-to-equity ratio of 0.42.

Analysts Set New Price Targets

On May 4, 2026, D. Boral Capital maintained its 'buy' rating for MediciNova, setting a price target of $9.00. Earlier, Maxim Group reinstated a 'buy' rating with a $6.00 target on March 23, 2026. HC Wainwright & Co. initiated coverage with a 'buy' rating and a $10.00 price target on March 16, 2026. The consensus among analysts is a 'buy' rating, with an average target price of $9.00 based on three opinions.

About MediciNova

MediciNova, Inc. is a biopharmaceutical company based in La Jolla, California, focusing on developing new treatments for serious diseases with unmet medical needs. It is working on MN-166, an oral anti-inflammatory agent in Phase 2 trials for neurological disorders, and MN-001, a compound targeting fibrotic and metabolic disorders. The company was founded in 2000 and is led by CEO Dr. Yuichi Iwaki.

Bottom Line

Insider purchases, like those by Nicole Lemerond, often attract attention as they can signal confidence in the company's prospects. MediciNova's stock is watched by investors for its potential in developing novel therapies. Analysts maintain a positive outlook, though the company's lack of profitability is a factor to consider. As always, it's important to remember that this information reflects past events and may not indicate current positions or future performance.